Table 2 Pooled results of head-to-head studies.
Treatment regimen | Number of trials | Brain metastases cases n1 vs n2 | Pooled survival data | Pooled HR or OR (95% CI) |
|---|---|---|---|---|
OS, months | ||||
1G EGFR-TKIs + VEGF mAb vs 1G EGFR-TKIs | 3 | 109 vs 113 | NA | 0.70 (0.43–0.97) |
2G EGFR-TKIs vs 1G EGFR-TKIs | 1 | 26 vs 24 | NA | 1.16 (0.61–2.21) |
3G EGFR-TKIs vs 1G EGFR-TKIs | 2 | 70 vs 84 | NA | 0.85 (0.51–1.20) |
1G EGFR-TKIs + CT vs 1G EGFR-TKIs | 2 | 130 vs 119 | NA | 0.68 (0.46–0.90) |
3G EGFR-TKIs + CT vs 3G EGFR-TKIs | 1 | 116 vs 110 | NA | 0.59 (0.4–0.87) |
PFS, months | ||||
1G EGFR-TKIs + VEGF mAb vs 1G EGFR-TKIs | 3 | 109 vs 113 | 18.18 (16.04 -20.32) vs 11.0 (9.69–12.31) | 0.55 (0.35–0.74) |
2G EGFR-TKIs + VEGF mAb vs 2G EGFR-TKIs | 1 | 13 vs 19 | 17.7 (9.8–21.9) vs 11.7 (4.2–18.7) | 0.52 (0.20–1.33) |
3G EGFR-TKIs + VEGF mAb vs 3G EGFR-TKIs | 1 | 18 vs 23 | NA | 0.83 (0.360–1.93) |
3G EGFR-TKIs + VEGFR mAb vs 3G EGFR-TKIs | 2 | 56 vs 42 | NA | 0.65 (0.28–1.03) |
1G EGFR-TKIs + VEGFR TKI vs 1G EGFR-TKIs | 1 | 51 vs 41 | NA | 0.91 (0.5–1.64) |
2G EGFR-TKIs vs 1G EGFR-TKIs | 1 | 26 vs 24 | 7.2 (3.7–17) vs 7.4 (5.4–12.8) | 0.76 (0.41–1.44) |
3G EGFR-TKIs vs 1G EGFR-TKIs | 9 | 589 vs 581 | 10.18 (9.46–10.90) vs 8.25 (7.70–8.79) | 0.46 (0.35–0.56) |
1G EGFR-TKIs + CT vs 1G EGFR-TKIs | 3 | 160 vs 153 | NA | 0.375 (0.27–0.48) |
3G EGFR-TKIs + CT vs 3G EGFR-TKIs | 1 | 116 vs 110 | 24.9 (22-NC) vs 13.8 (11–16.7) | 0.47 (0.33–0.66) |
3G EGFR-TKIs + EGFR-Met BsAb vs 3G EGFR-TKIs | 1 | 176 vs 176 | 18.3 (16.6–23.7) vs 13 (12.2–16.4) | 0.69 (0.53–0.92) |
iPFS, months | ||||
1G EGFR-TKIs + VEGF mAb vs 1G EGFR-TKIs | 1 | 29 vs 30 | NA | 0.18 (0.05–0.67) |
3G EGFR-TKIs vs 1G EGFR-TKIs | 6 | 501 vs 501 | 16.98 (14.13–19.83) vs 8.32 (7.64–9.01) | 0.43 (0.34–0.52) |
1G EGFR-TKIs + CT vs 1G EGFR-TKIs | 1 | 80 vs 81 | 15.6 (14.3–16.9) vs 9.1 (8–10.2) | 0.36 (0.25–0.53) |
3G EGFR-TKIs + CT vs 3G EGFR-TKIs | 1 | 118 vs 104 | NA | 0.58 (0.33–1.01) |
iORR | ||||
3G EGFR-TKIs vs 1G EGFR-TKIs | 6 | 502 vs 504 | 82% (74.6–89.4%) vs 54.7% (46.1–63.2%) | 1.82 (1.01–2.62) |
1G EGFR-TKIs + CT vs 1G EGFR-TKIs | 1 | 80 vs 81 | 85% vs 63% | 3.33 (1.56–7.14) |
3G EGFR-TKIs + CT vs 3G EGFR-TKIs | 1 | 116 vs 110 | 73% (64–81%) vs 69% (59–78%) | 1.19 (0.67–2.14) |
iDCR | ||||
3G EGFR-TKIs vs 1G EGFR-TKIs | 3 | 160 vs 170 | 94.4% (88.7–100%) vs 95.2% (89.9–100%) | 0.63 (-1.18–2.44) |
1G EGFR-TKIs + CT vs 1G EGFR-TKIs | 1 | 80 vs 81 | 95% vs 93.8% | 1.25 (0.32–4.84) |
3G EGFR-TKIs + CT vs 3G EGFR-TKIs | 1 | 116 vs 110 | 91% (84–95%) vs 93% (87–97%) | 0.70 (0.26–1.88) |
iDOR | ||||
3G EGFR-TKIs vs 1G EGFR-TKIs | 2 | 116 vs 117 | – | 0.22 (0.03–0.40) |
